Cart
sales@molnova.com
WUN29654
CAS No. 2407829-65-4
WUN29654( CRBN modulator-1 )
Catalog No. M24102 CAS No. 2407829-65-4
WUN29654 is a Thalidomide analog and CRBN modulator,has an IC50 of 3.5 μM and a Ki of 0.98 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 75 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 112 | In Stock |
|
| 25MG | 212 | In Stock |
|
| 50MG | 310 | In Stock |
|
| 100MG | 436 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWUN29654
-
NoteResearch use only, not for human use.
-
Brief DescriptionWUN29654 is a Thalidomide analog and CRBN modulator,has an IC50 of 3.5 μM and a Ki of 0.98 μM.
-
DescriptionWUN29654 is a Thalidomide analog and CRBN modulator,has an IC50 of 3.5 μM and a Ki of 0.98 μM.
-
In Vitro——
-
In Vivo——
-
SynonymsCRBN modulator-1
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2407829-65-4
-
Formula Weight324.29
-
Molecular FormulaC17H12N2O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=C(C1=C2C(C=C(O)C=C23)=CC=C1)N(C4CCC(NC4=O)=O)C3=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nathanael Gray, et al. New crbn modulators. WO2020006262A1.
molnova catalog
related products
-
guan-fu base G
Guanfu base G is an antiarrhythmic alkaloid isolated from Aconitum coreanum. Guanfu base G inhibits HERG channel current with an IC50 of 17.9 μM.
-
Agmatine sulfate sal...
Agmatine sulfate is a bioactive metabolite of the arginine amino acid. It exerts modulatory action at multiple molecular targets such as neurotransmitter systems ion channels and nitric oxide synthesis. It is an endogenous agonist at imidazoline receptor and a NO synthase inhibitor.
-
30-Hydroxygambogic a...
30-Hydroxygambogic acid exhibits significant cytotoxicities against the human leukemia K562/S and the corresponding doxorubicin-resistant K562/R cell lines.
